Exelixis Inc
$13.96B- Market cap
- $14.62B
- Debt
- +$399.32M
- Cash
- −$1.06B
Capital structure 97% equity / 3% debt · EV / Revenue 6.02x · EV / EBITDA 14.83x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $14.62B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: EXEL stock price at premium vs VTRS $59.01 current versus $12.70 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VTRS's multiple
Implied fair value · at EXEL's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXEL FY 2026 (ended Jan 2, 2026) · VTRS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 6.02x · EV / EBITDA 14.83x
Capital structure 57% equity / 43% debt · EV / Revenue 2.27x · EV / EBITDA 1393.83x
VTRS carries the larger enterprise value at $32.48B against $13.96B; VTRS trades on the lower EV / Revenue multiple (2.27x vs 6.02x); EXEL on the lower EV / EBITDA (14.83x vs 1393.83x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Exelixis Inc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
VIATRIS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.18x
0.98x
Net debt / EBITDA
Leverage against operating earnings
-0.70x
561.72x
Cash and equivalents
Liquid reserves on the balance sheet
$1.06B
$1.32B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
EXEL vs AMGN
BIOGEN INC.
EXEL vs BIIB
GILEAD SCIENCES, INC.
EXEL vs GILD
INCYTE CORP
EXEL vs INCY
Sarepta Therapeutics, Inc.
EXEL vs SRPT
PFIZER INC
EXEL vs PFE
Organon & Co.
EXEL vs OGN
BRISTOL MYERS SQUIBB CO
EXEL vs BMY
AbbVie Inc.
EXEL vs ABBV
Merck & Co., Inc.
EXEL vs MRK
$399.32M
$14.41B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.